Previous 10 |
AcelRx Pharmaceuticals ( ACRX +26.4% ) is up on a 10x surge in volume on expectations of a positive vote from an FDA advisory committee this Friday related to pain med DSUVIA (sufentanil sublingual tablet). Shares were down over 50% at one time premarket before recovering. Mo...
AcelRx Pharmaceuticals (NASDAQ: ACRX ) will likely be under pressure following the release of briefing materials for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for DSUVIA (sufentanil sublingual tablet) for the management of mo...
CIG +23% . More news on: Companhia Energtica de Minas Gerais - CEMIG, Petrobras - Petroleo Brasileiro S.A., India Globalization Capital, Inc, Stocks on the move, , Top stock market news, Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Banks and interest rates are set to dominate the discussion next week after Treasur...
Noteworthy events during the week of October 7 - 13 for healthcare investors. More news on: Inspire Medical Systems, Inc., OptiNose, Inc., Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
REDWOOD CITY, Calif. , Sept. 25, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management...
NEW YORK, NY / ACCESSWIRE / September 25, 2018 / Shares of Amarin Corporation were on fire on Monday after the company reported top line data results on Vascepa, the first Pure EPA prescription Omega-3 clinically proven to lower very high triglyceride,s without raising bad cholesterol (LDL-...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...